<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03361839</url>
  </required_header>
  <id_info>
    <org_study_id>example -1</org_study_id>
    <nct_id>NCT03361839</nct_id>
  </id_info>
  <brief_title>Endometrial Receptivity in Patients With Recurrent Implantation Failure as a Preparatory Step for PET</brief_title>
  <official_title>Clinical Trail for Study Endometrial Receptivity in RIF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      clinical trial to improve pregnancy outcome in patient with RLF , study done on 2 phases.&#xD;
      phase 1 to study variations of endometrial receptivity genes in this group of patient, phase&#xD;
      2 repeat cycle or transfer frozen embryo in proper time and after giving proper treatment&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design: Nonrandomized clinical trial&#xD;
&#xD;
      Inclusion criteria: women with history of recurrent implantation failure with History of&#xD;
      transfer of at least 4 good quality embryos in at least 3 fresh or frozen cycles&#xD;
&#xD;
        -  Women age less than 40 years&#xD;
&#xD;
             -  BMI (25 - 33)&#xD;
&#xD;
             -  Non diabetic Arms of study: 2&#xD;
&#xD;
                  1. Women for frozen embryo transfer or New ICSI cycle fulfilling previous&#xD;
                     criteria (study arm).&#xD;
&#xD;
                  2. Control group of fertile patient (fertile patients receiving local mechanical&#xD;
                     contraception as a reference group). To help in identification of cut off&#xD;
                     values of all related genes.&#xD;
&#xD;
                     Sample size: 60 Intervention&#xD;
&#xD;
                     Phase 1&#xD;
&#xD;
                  1. Recent labs ( day 2 serum FSH,LH TSH , PROLACTIN serum E 2)within 6 ms&#xD;
&#xD;
                  2. White tablets of cycloprogenova 4 mg /12 hs twice / day&#xD;
&#xD;
                  3. Add progesterone on (day 9) 600 mg per day.&#xD;
&#xD;
                  4. On day 5 of start progesterone do endometrial biopsy using pipplle endometrial&#xD;
                     suction curette&#xD;
&#xD;
                  5. Indirect immunofluorescence using QRT-PCR of the endometrial tissue for 11&#xD;
                     genes necessary for implantation and maintenance of pregnancy. Classify EB as&#xD;
                     pre-receptive, receptive and post receptive and plan next day of transfer.&#xD;
&#xD;
                  6. Genes to be studied: the most accessible genes will be studied.&#xD;
&#xD;
                  1. Homeobox gene (HOXA-10 ) upregulated&#xD;
&#xD;
                  2. LIF upregulated&#xD;
&#xD;
                  3. Alpha VB3 integren and its ligand osteopontin are positively detected&#xD;
&#xD;
                  4. ECM upregulated&#xD;
&#xD;
                  5. Paracrine stromal factors, +ve (EGF (epidermal growth factor), heparin binding&#xD;
                     EGF)&#xD;
&#xD;
        -  VE 17 B estradiol (E2 factors) 6- L selectin upregulated 7- E-cadherin ( downregulated)&#xD;
           8- Intercellular cell adhesion molecules highly expressed 9- Mucin 1 down regulated at&#xD;
           implantation 10- IL-6 upregulated 11- IL-1 and IL- 1 R upregulated 12- Prostaglandin&#xD;
           transporter (PGT) reduced in mid-late secretory. Phase 2 7- In the study arm Next cycle&#xD;
           start active ttt cycle of frozen ET( white tablet of Cycloprogenova twice daily then at&#xD;
           day 9 do transvaginal US when endometrial thickness is more than 9 mm start progesterone&#xD;
           till day 5 for transfer of frozen embryos or new ICSI cycle according to standard&#xD;
           protocol ( long or antagonist protocols according to every patient data ). then select&#xD;
           one of the suggested treatment&#xD;
&#xD;
             1. Intrauterine injection of human chorionic gonadotropins before transfer&#xD;
&#xD;
             2. Granulocyte colony stimulating factor given intrauterine ( 300 mcg /ml on day of OP&#xD;
                or progesterone administration of FET&#xD;
&#xD;
             3. Recombinant LIF&#xD;
&#xD;
             4. Or combination of 1 and 2 Common measures to be done in any situation&#xD;
&#xD;
             1. Low dose aspirin 75 mg daily&#xD;
&#xD;
             2. Steroids 5 mg hostacortin daily&#xD;
&#xD;
             3. Endometrial injury cycle before active cycle treatment&#xD;
&#xD;
           8- Technique of QRT-PCR of endometrial receptivity genes RNA Extraction Cells of all&#xD;
           studied groups will be lysed and total RNA was isolated with RNAeasy Mini Kit (Qiagen)&#xD;
           and further analyzed for quantity and quality with Beckman dual spectrophotometer (USA).&#xD;
&#xD;
      Real Time PCR (qRT-PCR) For quantitative expression of HOXA-10, LIF, Alpha VB3 integren and&#xD;
      its ligand osteopontin, ECM, EGF, E2 FACTOR, L-selectin, E-cadherin, ICAM, Mucin1, IL-6, IL1,&#xD;
      IL-1R and PGT; the following procedure will bes assessed. 10 ng of the total RNA from each&#xD;
      sample will be used for cDNA synthesis by reverse transcription using High capacity cDNA&#xD;
      Reverse Transcriptase kit (Applied Biosystem, USA). The cDNA will be subsequently amplified&#xD;
      with the Syber Green I PCR Master Kit (Fermentas) in a 48-well plate using the Step One&#xD;
      instrument (Applied Biosystem, USA) as follows: 10 minutes at 95 ºC for enzyme activation&#xD;
      followed by 40 cycles of 15 seconds at 95ºC, 20 seconds at 55 ºC and 30 second at 72 ºC for&#xD;
      the amplification step. Changes in the expression of each target gene will be normalized&#xD;
      relative to the mean critical threshold (CT) values of β-actin as housekeeping gene by the&#xD;
      ΔΔCt method. We will use 1 μM of both primers specific for each target gene. DNA sequencing&#xD;
      will be assessed for all studied genes&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">December 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>non randomized</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical pregnancy rate</measure>
    <time_frame>two weeks after transfer</time_frame>
    <description>positive intrauterine sac</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>RIF , Endometrial Receptivity</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients with RIF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>fertile arm as r reference for result</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>endometrial biopsy</intervention_name>
    <description>endometrial biopsy for genetic study of endometrial receptivity</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  women with history of recurrent implantation failure with History of transfer of at&#xD;
             least 4 good quality embryos in at least 3 fresh or frozen cycles&#xD;
&#xD;
          -  Women age less than 40 years • BMI (25 - 33)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  diabetic women&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>abdelmegeed ramzy, professor</last_name>
    <role>Study Director</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>olfat ali, professor</last_name>
    <phone>01011866550</phone>
    <email>olfat_noh@hotmail.com</email>
  </overall_contact>
  <reference>
    <citation>Nejat EJ, Ruiz-Alonso M, Simón C, Meier UT. Timing the window of implantation by nucleolar channel system prevalence matches the accuracy of the endometrial receptivity array. Fertil Steril. 2014 Nov;102(5):1477-81. doi: 10.1016/j.fertnstert.2014.07.1254. Epub 2014 Sep 17.</citation>
    <PMID>25241377</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>November 18, 2017</study_first_submitted>
  <study_first_submitted_qc>December 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2017</study_first_posted>
  <last_update_submitted>December 1, 2017</last_update_submitted>
  <last_update_submitted_qc>December 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Olfat Nooh Riad Ali</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>net results data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

